Article

Acuity foresees phase 1 trials for wet AMD drug

Acuity Pharmaceuticals on Aug. 10 filed an Investigational New Drug application (IND) with the FDA to initiate phase I clinical trials of Cand5, its lead product candidate for treatment of wet age-related macular degeneration (AMD).

Acuity Pharmaceuticals on Aug. 10 filed an Investigational New Drug application (IND) with the FDA to initiate phase I clinical trials of Cand5, its lead product candidate for treatment of wet age-related macular degeneration (AMD).

Cand5 is a small interfering RNA (siRNA) that uses the powerful mechanism of RNA interference (RNAi) to shut down genes that promote the overgrowth of blood vessels that lead to vision loss in wet AMD.

"Filing an IND for Cand5 is a milestone both for Acuity and for the new field of RNA interference," said Dale Pfost, PhD, president and chief executive officer of Acuity Pharmaceuticals, in a company statement. "This powerful technology has the potential to treat many diseases with greater efficacy and safety than current approaches, and Acuity Pharmaceuticals is proud to be the first to formally initiate the clinical trial process for an siRNA therapy. We believe that Acuity's pioneering status in advancing RNAi to the clinic and our strong intellectual property covering siRNA targeting VEGF reinforce our leadership in this exciting new field."

Cand5 shuts down the production of vascular endothelial growth factor (VEGF), which has been shown to be the central stimulus in the development of wet AMD as well as diabetic retinopathy. The efficacy of Cand5 in reducing the new blood vessel growth and leakage that cause AMD has already been demonstrated in primates and rodents. Its novel siRNA mechanism of action is expected to give Cand5 efficacy, safety, and administration advantages compared with other compounds in development for this condition.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.